Early Phase 1 Autoimmune Clinical Trials
26 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–20 of 26 trials
Recruiting
Early Phase 1
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Early Phase 1
Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Autoimmune
Janux Therapeutics60 enrolled1 locationNCT07291323
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)Autoimmune Hemolytic Anemia, AIHA+1 more
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Early Phase 1
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
AIHA - Warm Autoimmune Hemolytic AnemiaUCART
The Second Hospital of Anhui Medical University15 enrolled1 locationNCT07530380
Recruiting
Early Phase 1
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Early Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
Autoimmune Diseases
Ruijin Hospital66 enrolled3 locationsNCT06747156
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Sjogren's SyndromeAutoimmune DiseasesIdiopathic Inflammatory Myopathies+3 more
Nanjing Bioheng Biotech Co., Ltd.20 enrolled1 locationNCT06548607
Recruiting
Early Phase 1
Clinical Study of AFN50 Injection in the Autoimmune Diseases
Autoimmune Diseases
AlphaNa Bioscience Company Limited18 enrolled1 locationNCT07408336
Recruiting
Early Phase 1
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
Neurological Autoimmune Diseases
Juventas Cell Therapy Ltd.18 enrolled1 locationNCT07275736
Recruiting
Early Phase 1
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
Autoimmune Hemolytic AnemiaEvans SyndromePrimary Immune Thrombocytopenic Purpura
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology27 enrolled1 locationNCT07441525
Recruiting
Early Phase 1
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Early Phase 1
Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases
CARAutoimmune DiseasesPaediatric B Cell-related Autoimmune Diseases
The Children's Hospital of Zhejiang University School of Medicine12 enrolled1 locationNCT07283315
Recruiting
Early Phase 1
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Ruijin Hospital27 enrolled1 locationNCT07322718
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting
Early Phase 1
CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
Autoimmune Diseases
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06680388
Recruiting
Early Phase 1
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Early Phase 1
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799